Clinical trial NCT05467722: Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
Official title: A Phase 1 Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of CTP-543 (Deuruxolitinib Phosphate)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatic Impairment
Keywords: CTP-543
Lead sponsor: Concert Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2022-07-20
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.


Eligibility criteria: Inclusion Criteria:

* Adult males or females aged 18-75
* Body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2 at the time of screening
* If of reproductive age, willing and able to use a medically highly effective form of birth control 30 days prior to first dose, during the study and for 30 days following last dose of study medication
* Capable of giving informed consent and complying with study procedures

Additional Inclusion Criteria for Subjects with Hepatic Impairment:

* For moderate hepatic impairment, the subject must have a Child-Pugh score of 7 to 9 at the time of screening. For mild hepatic impairment, the subject must have a Child- Pugh score of 5 to 6 at the time of screening.
* No clinically significant change in disease status within the last 30 days before screening
* The subject must have a condition consistent with hepatic impairment and associated symptoms, but otherwise be determined to be healthy in the opinion of the Investigator
* If diabetic, the subject must have the disease controlled

Exclusion Criteria:

* History of any clinically significant medical condition, psychiatric disease, social condition, or illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study
* Known history of any GI surgery or any condition possibly affecting drug absorption
* History of prolonged QT syndrome or a QTc interval with Fridericia's correction (QTcF) \> 470 msec for males or QTcF \> 480 msec for females at Screening visit.
* Females who are nursing or pregnant prior to drug administration
* Positive for human immunodeficiency virus (HIV)
* Positive results for coronavirus infection (COVID-19) at screening or check-in
* Positive drugs of abuse or alcohol results at screening or check in (Day -1)

Additional Exclusion Criteria for Subjects with Hepatic Impairment:

* History or current diagnosis of uncontrolled or significant cardiac disease
* Gilbert's syndrome, liver transplant, Wilson's disease, autoimmune liver disease, esophageal variceal bleeding within 3 months prior to screening
* Previous diagnosis of hepatocellular carcinoma
* Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function

Primary outcomes:
measure: Single dose PK exposure: Maximum observed concentration (Cmax)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
measure: Single dose PK exposure: Area Under the Concentration-Time Curve from time zero to the time of the last observed/measured non-zero concentration (AUC0-t)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
measure: Single dose PK exposure: Area Under the Concentration-Time Curve from time 0 extrapolated to infinity (AUC0-inf)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 36, 48 hours post-dose
Secondary outcomes:
measure: Assessment of Safety and Tolerability following administration of CTP-543
timeFrame: Screening (within 21 days prior to Day 1) through follow-up (7 to 10 days after the final administration of study drug)
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Clinical Research Center
state: Florida
city: Knoxville
country: United States
facility: Alliance for Multispecialty Research, LLC
state: Tennessee
Study officials:
References: